Table 2.
Clinical trials using biomarkers as outcome measures
| Study title | Biomarkers | Participants | Phase | Clinical Trials. gov identifier |
|---|---|---|---|---|
| The Swedish BioFINDER 2 Study | Aβ42, tau, and phosphorylated tau | 1505 | Not applicable | NCT03174938 |
| KM-819 for patients with PD | KM-819, oligomeric α-synuclein, total tau, phosphorylated tau | 88 | 1 | NCT03022799 |
| Evaluation of a multimodal neuroimaging method for diagnosis in PD | Combination of biomarkers in multimodal imaging | 60 | 1 | NCT02428816 |
| Development of a novel 18F-DTBZ PET imaging as a biomarker to monitor neurodegeneration of PARK6 and PARK8 parkinsonism | 18F-DTBZ PET imaging | 49 | 2 | NCT01759888 |
| Single ascending dose study of MEDI1341 in healthy volunteers | Total α-synuclein | 40 | 1 | NCT03272165 |
| Effect of undenatured cysteine-rich whey protein isolate (HMS 90®) in patients with PD | Plasma glutathione, urinary 8-hydroxydeoxyguanosine, and urinary total antioxidant status | 38 | 4 | NCT01662414 |
| Florbetapir F18-PET imaging of beta-amyloid in PD patients | Aβ, tau, and phosphorylated tau | 31 | 2 | NCT00857532 |
| Ambroxol in disease modification in PD | GCase | 20 | 2 | NCT02941822 |
| Modulation of gut microbiota by Rifaximin in PD patients | Blood biomarkers of neuroinflammation and exosomal α-synuclein | 20 | 2 | NCT03958708 |
BioFINDER, biomarkers for identifying neurodegenerative disorders early and reliably; KM-819, Fas-associated factor 1 inhibitor; DTBZ, dihydrotetrabenazine; PET, positron emission tomography; GCase, β-glucocerebrosidase.